|Articles|October 19, 2009
Emerging Pharma Leadership Awards - Elizabeth Mutisya
Advertisement
Elizabeth Mutisya,
VP, US Medical Affairs, CMO,
Solvay Pharmaceuticals
Download Adobe Flash Player
“We need to do a better job of delineating the value our industry provides in addressing medical problems. Health economics allows us to better quantify the benefits of our solutions to patient outcomes, health-related quality of life, and individuals involved in patient care.” Listen to the Podcast for more coverage.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
3
The Evolving Relationship Between FDA and Biotech
4
What Kinds of Disruption are GLP-1s Expected to Face
5